Impact Factor 4.003 | CiteScore 4.0

More on impact ›

SYSTEMATIC REVIEW article

Front. Neurol., 27 August 2021 | https://doi.org/10.3389/fneur.2021.716632

Cognitive Impairment After Intracerebral Hemorrhage: A Systematic Review of Current Evidence and Knowledge Gaps

  • 1Center for Outcomes Research, Houston Methodist Research Institute, Houston Methodist, Houston, TX, United States
  • 2Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, United States
  • 3Department of Nuclear Engineering, Texas A&M University, College Station, TX, United States
  • 4Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States
  • 5Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States
  • 6Neurological Institute, Houston Methodist, Houston, TX, United States

Background: Cognitive impairment (CI) is commonly observed after intracerebral hemorrhage (ICH). While a growing number of studies have explored this association, several evidence gaps persist. This review seeks to investigate the relationship between CI and ICH.

Methods: A two-stage systematic review of research articles, clinical trials, and case series was performed. Initial search used the keywords [“Intracerebral hemorrhage” OR “ICH”] AND [“Cognitive Impairment” OR “Dementia OR “Cognitive Decline”] within the PubMed (last accessed November 3rd, 2020) and ScienceDirect (last accessed October 27th, 2020) databases, without publication date limits. Articles that addressed CI and spontaneous ICH were accepted if CI was assessed after ICH. Articles were rejected if they did not independently address an adult human population or spontaneous ICH, didn't link CI to ICH, were an unrelated document type, or were not written in English. A secondary snowball literature search was performed using reviews identified by the initial search. The Agency for Healthcare research and Quality's assessment tool was used to evaluate bias within studies. Rates of CI and contributory factors were investigated.

Results: Search yielded 32 articles that collectively included 22,631 patients. Present evidence indicates a high rate of post-ICH CI (65–84%) in the acute phase (<4 weeks) which is relatively lower at 3 (17.3–40.2%) and 6 months (19–63.3%). Longer term follow-up (≥1 year) demonstrates a gradual increase in CI. Advanced age, female sex, and prior stroke were associated with higher rates of CI. Associations between post-ICH CI and cerebral microbleeds, superficial siderosis, and ICH volume also exist. Pre-ICH cognitive assessment was missing in 28% of included studies. The Mini Mental State Evaluation (44%) and Montreal Cognitive Assessment (16%) were the most common cognitive assessments, albeit with variable thresholds and definitions. Studies rarely (<10%) addressed racial and ethnic disparities.

Discussion: Current findings suggest a dynamic course of post-ICH cognitive impairment that may depend on genetic, sociodemographic and clinical factors. Methodological heterogeneity prevented meta-analysis, limiting results. There is a need for the methodologies and time points of post-ICH cognitive assessments to be harmonized across diverse clinical and demographic populations.

Introduction

Intracerebral hemorrhage (ICH) is the most common type of hemorrhagic stroke, accounting for 10–20% of all strokes (1), with a global incidence of 24.6 per 100,000 person-years (2). Spontaneous ICH primarily results from either hypertensive microangiopathy or cerebral amyloid angiopathy (CAA) (3), which are likely to produce varied phenotypes. Hypertensive ICH likely occurs in deep brain structures while CAA-related ICH generally occurs in lobar locations (2). Regardless of the cause, ICH is associated with poor outcomes that include early mortality (2, 4) and the loss of functional independence (2).

Cognitive Impairment (CI) commonly coexists with ICH. The majority of ICH patients exhibit acute phase CI, with impairments reported in up to 84% of patients (5). While the immediate post-ICH cognitive effects and the potential for long-term CI (6) are broadly recognized, several evidence gaps persist. The trajectory of post-ICH CI is poorly characterized and demonstrates considerable variability. Some ICH patients experience favorable recovery after an acute cognitive decline while others exhibit persistent or worsening CI (7). The significant contribution of cognitive function toward quality of life among ICH survivors has driven an increased research focus on post-ICH CI and dementia. With the growing body of literature focused on post-ICH CI, it is important to integrate the available evidence and characterize cognitive function among ICH patients. This systematic review aims to collect and summarize current evidence regarding the risk factors and trajectory of CI after spontaneous ICH, report the strength and validity of study methodologies, and highlight current knowledge gaps in the study of post-ICH CI.

Methods

Search Strategy

We adopted a two-stage systematic review approach to comprehensively account for all study types that have reported cognitive function among patients with spontaneous ICH, particularly focusing on post-ICH CI. Articles were to be excluded from consideration if they did not address the occurrence of CI after ICH, focused on animal or tissue models, assessed other/mixed stroke etiologies or traumatic ICH, or assessed a pediatric/neonatal population. First, a literature search within the PubMed and ScienceDirect databases was performed. Searches were performed using the keywords [“intracerebral hemorrhage” OR “ICH”] AND [“cognitive impairment,” OR “cognitive decline” OR “dementia”] to detect both abbreviated and unabbreviated descriptions. Searches were performed using Boolean logic with detection of alternative spellings (e.g., hemorrhage and hemorrhage) enabled. No limits were placed on date of publication, and databases were last accessed on November 3rd of 2020 (PubMed) and October 27th of 2020 (ScienceDirect). To enable inclusion of studies with higher methodological rigor, only peer-reviewed clinical trials, observational studies, and case series were included. After accounting for duplicates, articles were screened for inclusion. Narrative reviews, study protocols, animal studies, histological studies, editorial comments, expert opinions, abstracts lacking a full-text publication, and papers written in a non-English language were removed from initial assessment. Abstracts were then reviewed for the concepts related to ICH and CI or dementia and rejected if they failed to mention one or both. Abstracts were also rejected at this stage if they specified a pediatric population or addressed subarachnoid/traumatic ICH, ischemic stroke, or transient ischemic attacks. Abstracts that included non-specific terminology (e.g., “stroke” instead of specifying ischemic or hemorrhagic etiologies) were included for further review. Full texts were then reviewed for all articles that did not meet the rejection criteria. Articles that made use of a mixed stroke cohort without delineation were excluded, as were studies that only assessed CI before or independent of ICH. Data were independently extracted from included studies and, when available, included study design, sample size, country of origin, follow up time, neuropsychological assessments and thresholds, imaging methods and assessed markers, other assessments, clinical/social factors and medications, overall rates of CI, factors significantly associated with CI, and other outcome notes. No separate review protocol has been registered or published for this study.

To supplement the initial review, a secondary snowball review was performed based on the articles returned by the original search methodology; as has been recommended in published literature (8). Publications were screened for discussions that linked CI to ICH, and cited articles were examined for information regarding post-ICH CI in the same manner as articles obtained by database search.

Data Extraction

Articles were assessed for methodology, neuropsychological assessments, imaging findings, other clinical assessments, other factors, and study results, and data were extracted within these categories. Recorded methodology included the study design (cross-sectional, clinical trial, case-control, cohort, etc.), country of origin, number of ICH patients, and follow-up times. Cognitive assessment details included testing methods and thresholds used to define CI and/or dementia. Imaging measures included the applied modalities and features assessed. “Other clinical assessments” included assessments which address factors other than CI (stroke severity, depression, disability, etc.). Notably, stroke laterality was variably assigned between “Imaging” and “Other Clinical Assessments” depending on whether assessment was linked to imaging within the assessed document. Data retained as “other factors” included clinical risk factors and/or laboratory values (comorbidities, etc.), social risk factors (smoking history, alcohol consumption, education, race, etc.), and medications. Each study was assessed for the observed or reported CI percentage at follow-up, hazard rates, impairment domains, other listed cognitive outcomes, factors associated with CI, and other outcome notes. Impairment percentage was calculated based on patient numbers when not independently reported for ICH patients. Data were independently extracted by the lead author (TP) and checked for quality and validated by other authors (JM, AP, and FV). All data for this review was stored within an internal database for reference and reproducibility.

Risk of Bias Assessment

The risk of bias for each study was assessed following the Agency for Healthcare Research and Quality's (AHRQ) bias assessment tool, classifying risk as low, medium high, or unclear (9). Briefly, the AHRQ tool provides a design-specific method for assessing bias in scientific studies. Specific attention is paid to the recruitment, allocation, and retention of individuals within study groups, protocol consistency, use of outcome measures, and the complete reporting of outcomes.

Statistical Methods

Sample sizes and proportions of ICH patients with CI across the follow-up timeline were extracted for assessment. Follow-up times were also recorded and are reported (median, mean, or set times). The maximum, minimum, and average reported CI proportion (measured as a percentage) was determined at each follow-up time, and these values were used to assess the overall trajectory of CI after ICH. Given the heterogeneity and lack of information about ICH clinical phenotypes and variety of CI assessment methods employed across a spectrum of post-ICH timepoints no meta-analytic methods were applied for data pooling and summarization. Detailed descriptive accounts of study characteristics, post-ICH CI, assessment methods, imaging findings, and clinical and socio-demographic factors are provided.

Results

Following the outlined search criteria and syntax 300 articles were identified from the PubMed database with additional 89 records obtained from the ScienceDirect database. Forty-nine overlapping records were removed. Additional articles were removed for the following reasons: were a protocol, opinion review, textbook chapter, meeting proceedings, or other unrelated document type (n = 165), were not available in English (n = 16), did not address CI and/or spontaneous ICH in an adult population (n = 101), assessed pediatric or traumatic ICH (n = 4), assessed CI before ICH (n = 18), assessed the CI separately from ICH (n = 11), or assessed a mixed stroke cohort (n = 2). This yielded 23 total articles obtained from literature review. After identifying more sources of interest within the references of conceptually related reviews, a secondary snowball literature was performed based on the reviews identified from initial search. This search yielded nine additional sources, which were combined with the initial search results to form the final set of works for review (n = 32). An overview of the literature selection process is depicted in Figure 1. Of the 32 selected studies, 19 (59.4%) were observational cohorts, 8 (25.0%) were case-control studies and 3 (9.4%) were cross-sectional analyses. Additionally, data from 1 (3.1%) randomized control trial (RCT) and case series were included. Studies cumulatively included 22,631 ICH patients. The content of reviewed studies can be found in Tables 13, with cohort studies presented in Table 1, case-control studies in Table 2, and other studies in Table 3. Assessed risks of bias for each study are presented in Table 4. Of the 32 assessed studies, 31 (96.9%) studies were found to be of “acceptable” risk of bias. The lone exception was a limited case series and of unclear bias due to the limited details presented. Fourteen studies (43.8%) excluded patients with severe aphasia. Of these, 11 studies excluded 62 patients who could not communicate or follow directions (11, 14, 2123, 25, 27, 29, 31, 33, 38) while the three remaining studies excluded aphasia without providing the number excluded (10, 15, 16). Eleven studies (34.4%) only included living patients and did not account for potential survivorship bias within the studied ICH population (12, 14, 21, 22, 24, 26, 30, 33, 34, 36, 38). Though the overall bias risk was acceptable, one study (3.2%) also had a significant difference in follow-up times between the ICH and non-ICH study groups (30).

FIGURE 1
www.frontiersin.org

Figure 1. Consort diagram for the selection of studies. A total of 32 studies were selected from the Science Direct and PubMed databases, with screening performed to remove articles that did not address post-ICH CI or non-spontaneous adult ICH cases.

TABLE 1
www.frontiersin.org

Table 1. Summary of methods and findings from cohort studies.

TABLE 2
www.frontiersin.org

Table 2. Summary of methods and findings from case-control studies.

TABLE 3
www.frontiersin.org

Table 3. Summary of methods and findings from other study types.

TABLE 4
www.frontiersin.org

Table 4. Assessment of risk for included studies, following AHRQ guidelines.

Study Characteristics

Among the 32 included studies, 19 (59.4%) publications provided investigations of the various factors that contribute to the development of post-ICH CI. The remaining 13 (40.6%) were either limited in their scope to only describe the observed rate of CI or included heterogenous stroke sub-types, among which ICH was a reported subgroup. Study populations were drawn from the United States (n = 5), France (n = 4), Japan (n = 3), Norway (n = 3), the Netherlands (n = 2), England (n = 2), China (n = 2), Taiwan (n = 2), 1 each from Finland, Spain, Italy, Scotland, Ecuador, Denmark, Mexico, and Portugal, and 1 international study. Four studies (12.5%) presented fewer than 10 patients (10, 30, 34, 35), of which three studies included ICH only as an sub-group of a larger stroke cohort (10, 30, 34) and the fourth presented as a limited case series (35). In contrast, two studies contained over 1,000 participants each (6, 40). These were large, retrospective national investigations of long-term patient outcomes from Denmark (6) and Taiwan (40). Follow up times were similarly variable, with some studies selecting specific timings to investigate acute and early post-ICH CI/Dementia (<6 months) compared to late post-ICH CI/Dementia (>6 months). Overall, the times for follow-up assessment varied from 12 days to 10 years, with timepoints of 3 months/90 days [10 (29.0%)], 6 months [7 (21.9%)], and 1 year [6 (18.8%)] being the most common. Studies that performed recurrent testing had a minimum test-retest interval of 3 months [1 (3.1%)] and typically assumed annual [5 (15.6%)] or semiannual [2 (6.3%)] testing after the first follow-up. The varying study methods, including the range of follow-up times, are summarized in Table 5.

TABLE 5
www.frontiersin.org

Table 5. The variable testing methods and parameters adopted across studies of post-ICH impairment.

Post-ICH Cognitive Impairment Over Time and Contributory Factors

Across studies, the potential impact of preexisting cognitive deficits on post-ICH CI was generally acknowledged. To address this, 13 (40.6%) studies excluded individuals with pre-ICH CI or dementia (7, 10, 13, 16, 19, 22, 25, 2931, 33, 37, 40), [7 (21.9%)] or included patients with preexisting CI (11, 14, 18, 26, 35, 38, 39), either acknowledging the limitation [4 (12.5%)] (14, 18, 35, 38) or including pre-stroke deficits as a contributory factor for future CI [3 (9.4%)] (11, 26, 39). Three additional studies chose to selectively exclude patients that met the criteria for dementia but included patients with mild impairments, using preexisting dementia as a contributory factor for future deficits (12, 23, 28). The remaining studies [9 (28.1%)] either did not assess or report on preexisting CI (5, 6, 15, 21, 24, 27, 32, 34, 36).

Cognitive impairment reported after the onset of ICH varied considerably across the time horizon. Figure 2 depicts the proportions of ICH patients with post-ICH CI at various timepoints, with 3rd-order polynomial trendlines reflecting the maximum, minimum, and average observed CI proportions. Table 6 provides a summary of the significant imaging, demographic and clinical factors significantly associated with post-ICH CI across the studies included in this review.

FIGURE 2
www.frontiersin.org

Figure 2. Plot of post-ICH CI percentages, with trendlines reflecting the maximum, minimum, and average observed CI proportions. Data for the maximum, average, and minimum data points are, respectively, shown by the black, gray, and open white markers. Respective CI trends are shown using black, gray, and dashed lines. Impairment appeared highest during the acute phase, dropped to a minimum during the 20–24-month timespan, and steadily increased over the remaining observed timespan.

TABLE 6
www.frontiersin.org

Table 6. Summary of significant factors identified across reports included in the review.

The three acute phase studies reported that 84.0% of ICH patients demonstrated impairment in one or more cognitive domain at 12 days post-stroke (5, 16, 31), with 65.0% showing impairment in two or more domains (5), 75.2% of patients impaired at 2 weeks (16) and 82.4% of patients showing 2+ domain impairment at 3 weeks (31). Of the 3 studies, 1 assessed for delirium before testing (41) and 2 assessed for disorders of consciousness and aphasia (16, 31). Lobar and dominant-hemisphere ICH, and increased admission systolic blood pressure (SBP) were noted as factors associated with CI in this period (5, 16). Specifically, patients with lobar ICH showed higher rates of impairment in two or more domains (73.0% lobar vs. 58.0% non-lobar) while dominant-hemisphere hemorrhage and higher SBP showed respective odds ratios (OR) of 8.85 and 1.02 for impairment.

Impairment rates at 3 months post-ICH were reported to range from 17.3 to 40.2% (11, 15, 26, 37). Different studies demonstrated association between CI and Hispanic ethnicity (vs. non-Hispanic White) (18) and female sex (37)—Hispanic ICH patients presented with mental state examination (MSE) scores that were on the average 13.3 points lower than their non-Hispanic counterparts. Additionally, proportion of females with post-ICH CI during this time point was significantly higher than males (45.3 vs. 30.8%). Cognitive impairment during the 3 month post-ICH time period was also associated with increased hematoma volume—hazard ratio [(HR) 1.52 per 10 cc increase], and APOE ε2 genotype (HR: 1.69) (13), prior history of stroke, older age, higher baseline CI, and higher SBP during the first 24 h (37). Higher education was associated with lower rates of post-ICH CI (22), and separate reports associated 3-month post-ICH CI with both deep (25) and lobar ICH locations (13).

Studies reporting data from 6 to 12 months post-ICH found CI rates between 19.0 and 63.3% (12, 13, 16). Higher levels of CI were associated with increased age (HR: 1.05 per year), lower education level (HR: 1.78), pre-existing mild CI (HR: 5.85), and African American race (HR: 1.39) (12, 13, 28). Impairment was further linked to the severity of several cerebral small vessel disease (CSVD) markers such as, white matter hyperintensities per total brain volume (HR: 1.48), Fazekas score (HR: 1.51), number of cortical microbleeds (CMBs) ≥ 5 (HR: 2.05), white matter disease severity (HR: 1.70), and lobar CMB number (HR: 1.78) and APOE ε4 genotype (HR: 2.12) (12, 13). Visuospatial, executive, attention, and memory were observed as the primarily affected domains, and CI appeared to associated with the laterality of ICH (16, 33)—ICH in the left basal ganglia was linked to visuospatial impairment, while those with right basal ganglia ICH performed worse in linguistic tasks (33) and left sided ICH was associated with increased dementia development (38).

The proportion of ICH patients with CI 1 year post-ICH were reported at 14.2% (23) and 43.8% (19), with an estimated HR of 4.34 for the 3–12 months period (6) and incidences between 20.7 and 24.8 per 1,000 person-years (6, 40). One study reported that CI probabilities reduced and language performance improved between 3 and 18 months post-ICH, although the study was underpowered (7). Reports in the 2nd year post-ICH found CI rates of 19.8% at 2 years (23), while a second study reported 35.8% either became impaired or died at a median of 28.9 months (39). CI rates were reported between 19.1 and 24.5% (23, 24) at 3 years. The respective rates of CI and dementia were reported as 47.4 and 23.1% at 40 months, with the note that 65.4% of survivor showed some level of persistent deficit (38). CI rates that depended on the applied Montreal Cognitive Assessment (MoCA) threshold (61.4% at MoCA ≤ 23 and 71% at MoCA ≤ 25) (27) were reported at 3.8 years post-ICH, with a CI rate of 28.3% separately reported at 4 years post-ICH (23). Study at 5 years post-ICH reported incidence of 14.6 per 1,000 persons years, with a model-dependent HR of 2.14 and 2.17 (40). The only report of independent CI rates at this timepoint assessed initially asymptomatic ICH patients, who did not show any difference from healthy individuals (32). Long-term assessments estimated incidence rates of 11.8 per 1,000 individuals per year at 10 years (40) and 13.6 over the 1–10 year period (6). Long-term CI was found to be associated with the number of recurrent stroke episodes (36). Age, modified Rankin Scale (mRS) scores, and lobar location were found to be significant factors, with lower MoCA scores associated with higher age and greater disability (21, 27). Finally, impaired individuals were found to have higher baseline and discharge national institutes of health stroke scale (NIHSS) scores, with higher C-reactive protein levels (CRP) and white blood cell counts (WBC) (24).

Cognitive Assessments

Across the included studies, the Information Questionnaire on Cognitive Decline in the Elderly (IQCODE) was utilized in 10 (31.3%) studies as the most-common test for pre-stroke cognitive function (1113, 18, 19, 23, 25, 26, 29, 31) [including uses of the short-IQCODE (31), Spanish IQCODE (11), and French IQCODE (23)]. However, IQCODE cutoffs varied greatly across studies (Table 5). IQCODE assessments adopted 4 different thresholds for “cognitive decline” or “impairment” (IQCODE >3.5, >3.44, ≥ 3.4, 63 ≥ IQCODE ≥ 53) with 2 more thresholds (IQCODE ≥ 64, > 3.3) applied to describe dementia. No single threshold was adopted by more than two studies.

Whereas the IQCODE was used relatively consistently to assess pre-morbid cognitive status, the methodology of assessment for post-ICH CI was highly variable. Global cognition tests were commonly applied, with the Mini-Mental State Evaluation (MMSE) adopted by 14 (43.8%) studies (11, 12, 15, 19, 22, 23, 25, 26, 30, 3234, 37, 38) and MoCA adopted by 5 (15.6%) (7, 16, 21, 27, 38). Thresholds set for CI included MMSE < 27, MMSE ≤ 24, MoCA < 26 and MoCA ≤ 23, with one study defining dementia at MMSE < 23 (30), and no threshold used by more than two studies (Table 5). Tiered CI definitions based on MMSE or MoCA were also established in three studies, with no studies sharing definitions (Table 5). One study adopted education-linked MMSE thresholds as a screening test for further assessment (22). Other studies made use of the Short MoCA (16), the Ascertain Dementia 8-item Informant (AD8) questionnaire (34), and the Modified MMSE (3MSE) (18), each with a singular use and threshold (short MoCA < 7, AD ≥ 2, 3MSE < 80) (Table 5). Studies based on telephone-based assessment adopted the modified Telephone Interview for Cognitive Status (TICS-m) (13), Telephone MoCA (T-MoCA) (7), or caregiver interview (39).

Beyond global cognition tests, 11 (34.4%) studies adopted test batteries to assess cognitive function, with the National Institute of Neurological Disease and Stroke—Canadian Stroke Network (NINDS-CSN) battery applied by two studies (7, 23) and the Frontal Assessment Battery (25), Consortium to Establish a Registry for Alzheimer's Disease (CERAD) battery (7), and Neuropsychiatric Battery (14) used by one study each. The remaining battery-based assessments used custom combinations of tests designed to assess different cognitive domains. In 13 (40.6%) studies, determination for CI was made based on general diagnosis (23, 36), DSM-IV (11, 14, 22, 24, 26, 29, 38), DSM-V (7), ICD-9 (40), and ICD-10 (6, 10, 19) diagnostic criteria. Finally, 5 (15.6%) defined CI by the relative decrease in function from baseline assessments (5, 28, 30, 33, 39).

Imaging Methods and Assessments

Of the total 32 studies, 17 (53.1%) included imaging markers either in assessment or analysis [five computed tomography (CT) only, four magnetic resonance imaging (MRI) only, seven CT and MRI, one CT or MRI]. The most common imaging markers reported were ICH characteristics, including location (11), laterality (8) and volume (9). ICH location description varied between studies, with 7 different location definitions adopted (Table 5). ICH volume was commonly assessed (13, 21, 23, 25, 27, 28, 32, 37, 38), with intraventricular extension accounted for by 7 (12.9%) studies (13, 16, 21, 27, 33, 37, 38). Markers of CSVD and CAA were also assessed with regularity, although the individual markers were inconsistently reported. Major imaging features included the presence of CMBs (12, 13, 23, 25, 28), lacunes (12, 23, 28), White Matter Hyperintensity (WMH) volume (28), WMH Fazekas scoring (12, 13, 16, 23, 25, 27, 28, 30), presence of enlarged perivascular spaces (28, 32), and Cortical Superficial Siderosis (CSS) (23, 25, 28). CSS assessments were dichotomized according to presence/absence (25) or focal/disseminated (23, 28) status, with respective significance found for presence (25) and disseminated CSS (23, 28). One study extended imaging features to determine a total CSVD score, which was used both nominally and dichotomized (<3 or ≥3) (28). Finally, focal brain atrophy (32) and global cortical atrophy (12, 23, 33) were, respectively, assessed in one and three studies. Across studies, ICH volume, CMBs, atrophy, white matter disease, CSS, and leukoaraiosis showed the greatest levels of significance.

Clinical and Sociodemographic Factors

The NIHSS was reported in 8 (25.8%) studies (7, 16, 18, 2325, 29, 37). Functional outcomes were reported as the Barthel index in 3 (9.7%) (7, 29, 38), the mRS in 8 (25.0%) (7, 18, 21, 23, 25, 38, 39), and Activity of Daily Life measurement (38). Depression linked to ICH was assessed using the Beck Depression Inventory (21, 25), Montgomery–Asberg Depression Rating Scale (MADRS) (12, 25, 38), Geriatric Depression Scale (30), Hamilton Depression Rating Scale (22) and the Hospital Anxiety and Depression Scale (21). Stroke laterality was reported in two studies without imaging details (7, 29). Assessment on the Glasgow Coma Scale was reported in four studies (18, 27, 33, 37).

Among demographic factors, age and sex/gender were, respectively, accounted for in 18 (56.3%) (5, 12, 13, 16, 18, 2125, 2730, 32, 33, 37, 39) and 15 studies (46.9%, 10 sex, five gender) (12, 16, 18, 2225, 2730, 32, 37, 39, 41), with education assessed in 13 (40.6%) (5, 12, 13, 16, 18, 22, 23, 25, 2730, 33). Notably, studies that did not address age and sex typically assessed ICH as a subgroup or as a case series. Pre-existing risk factors/comorbidities were most commonly reported for hypertension in 15 (46.9%) (13, 16, 18, 22, 24, 25, 2730, 32, 35, 3739), previous stroke or ICH in 11 (34.4%) (12, 13, 18, 22, 23, 25, 28, 32, 3739), atrial fibrillation in 7 (21.9%) (12, 13, 18, 22, 23, 27, 30) and diabetes mellitus in 12 (37.5%) (13, 16, 18, 22, 24, 25, 2730, 32, 37) studies. Anticoagulant therapy was not found to be a significant factor by either of the studies that assessed it (13, 37). The definition of education was inconsistent, and race/ethnicity was seldom reported, appearing in 3 (9.4%) studies and found to be a significantly associated factor by 2 (6.3%) (18, 32, 38). Marital status, assessed in one study (3.1%), was not significantly associated with post ICH CI (18). Two studies (6.3%) provided a greater emphasis on laboratory values and testing than other studies, including blood cell counts and protein levels (16, 24).

Discussion

Our review identified 32 full-text studies that assessed post-ICH CI. With the exception of a single study with a small ICH sample size (n = 5) (30), all studies found CI to be relatively common after ICH with links to a variety of clinical, social, imaging, and genetic factors. Studies were largely comprised of cohort and case-control studies and provided information from a variety of different patient populations. Impairment rate information obtained from the reviewed texts suggests relatively high rates of CI during the acute phase of ICH that drop off over the first 2 years post-ICH and increase afterwards. Although rates of CI were consistently reported to be high during the acute post-ICH phase, these findings are likely be an over estimate due to factors directly and indirectly related to acute neurological injury such as, medications, infections/sepsis, and delirium. The alleviation of these transient factors, combined with the effects of true cognitive recovery, create an apparent decrease in CI rates over the following 20–22-month period. Long-term assessments then depict a secondary rise in CI rates, although these measurements demonstrate high variability and may be subject to survivorship biases. In studies with repeated testing, training effects did not appear to be a major concern based on long test-retest intervals and a common reliance on diagnostic criteria or patient-specific testing. This risk of CI and death was found to be greater after ICH than in other stroke types (40), with impairments appearing primarily within the domains of visuospatial processing, processing speed, nonverbal IQ, executive function, attention, and memory (5, 33). Patients presenting with severe aphasia during the acute phase were largely unstudied due to testing limitations, however the low number of exclusions across studies makes significant bias unlikely. There is modest evidence that ICH location influences the affected domains (25), and lobar/CAA ICH was associated with poorer recovery and greater rates of post-ICH CI (13, 16, 23, 27). Lobar ICH was also associated with increased age (41), however, and it is unclear if this relationship may mediate cognitive outcomes. Variability in patient CI percentage increased over time, with CI rates of 19.1 and 71.0% both observed in the 3–4 year timespan (23, 24, 27, 38).

Although hypertensive microangiopathy constitutes a primary ICH etiological mechanism (25, 42, 43) and acute post-ICH SBP was associated with early cognitive deficits (16), a clear relationship between chronic hypertension and the development of CI has yet to be established among ICH patients. Similarly, despite evident links between CI and both atrial fibrillation and diabetes mellitus in the general population and mixed stroke populations (29, 4446), significant associations between these factors have not been reported in post-ICH cohorts. On the other hand, risk factors related to demographics and genetics (age, ethnicity/race, sex, and APOE genotype), presentation cerebral disease burden (CSVD characteristics, CSS, previous stroke, and hematoma volume) and other biological markers such as high WBC and CRP demonstrate a significant association with the development of post-ICH CI (12, 13, 16, 18, 21, 23, 24, 27, 28, 37).

Several of these factors—CSVD markers, CSS, and APOE genotypes—are also indicative of CAA, which has been associated to cognitive impairment and should be considered a condition of interest (17, 41, 47). The importance of acute-phase cerebral pathology is further supported by reports of similar CI rates observed between incidental asymptomatic ICH patients and their matched controls (32), and those with relatively preserved baseline cognitive status across the most commonly affected domains (visuospatial, executive, attention, orientation) (16, 41). Our review indicated that APOE ε2 and ε4 genotypes may, respectively, contribute to the early and late development of post-ICH CI (13). Contextually, this somewhat resembles the roles of the APOE genotypes in Alzheimer's disease (AD) and vascular dementia (VaD). Specifically, APOE ε2 has shown neuroprotective effects (48) and the early post-ICH deficits linked to it are transient, while APOE ε4 is a significant risk factor for VaD and AD (49) and the associated post-ICH CI show a delayed build over time. It is therefore possible that the role of APOE ε4 in the development of long-term CI among ICH survivors is related to pathways overlapping with VaD and AD, such as buildup of vascular risk factors, CAA, amyloid disease and aging, although this relationship will need to be clarified in future studies. Finally, increased attention should be paid to patient ethnicity/race, which as only addressed in 3 studies and found to be significant in 2. This may also suggest other factors of interest, as ethnicity often portends disparities social support, economic deprivation, healthcare access, and treatment (5052). Present evidence suggests that post-ICH CI may result from combined effects of damage during the acute phase of hemorrhage and pre-existing underlying arteriopathy, however continued research into post-ICH CI will be necessary to explore both the clinical and societal factors that are critical for patient recovery during the post-ICH period.

The stated focus of study—assessing the development of CI after ICH—appears straightforward. Unfortunately, research in this direction is host to many inconsistencies within the applied methods and assessments. Across the 32 included studies, 20 different impairment and dementia thresholds based on global cognition tests, eight different ICH location classifications, and six different education thresholds were established. Consequently, cases exist where patients assessed with “dementia” by one study would not meet others' minimum classification for “cognitive impairment” (13, 29). These inconsistent definitions, combined with their seldom re-use, limit specific sub-analysis. Chosen assessments were presented across 16 different post-ICH timepoints, with 23 of the 32 studies testing at the 3, 6, and 12-month timepoints. Though we believe that this work provides a valuable summary of post-ICH CI, considerable variability in testing parameters adds significant uncertainty to the results and limits the ability to pool quantitative estimates across consistent timepoints. To assuage this, future efforts should seek to establish and adhere to a standardized assessment protocols, which can be supplemented with additional testing to suit specific research questions and domain areas. Efforts should also be made to specifically explore additional timepoints, particularly over an extended time horizon.

Future Directions and Considerations

Although literature is beginning to emerge, several gaps persist in our understanding of post-ICH CI, its associated factors, and its temporal trajectories. Presently, the greatest needs appear to be those of standardization in measurement and assessment of CI along with precise quantification of pre-ICH cognitive function. This discussion is considered too large to be held within the context of this singular review, and a full consideration of existing assessment methods should be made within the context of the domains commonly affected by ICH. Larger cohorts of ICH patients with wide-ranging impairments and well-defined clinical, social, and radiological phenotypes also need to be assessed, using standardized scales and criteria at consistently defined and clinically meaningful time points over a long-term horizon of post-ICH recovery. The establishment of a concise and easily referenced testing methodology would also provide firm grounding for comparison and pooling of estimates across studies. Future studies are encouraged to, at minimum, account for attrition and survivorship biases, along with history, number, and recurrence of stroke-type events. Imaging studies should assess ICH volume, CMBs, and CSS at minimum, ideally assessing the full spectrum of CSVD markers and considering the potential for CAA. Assessments of potential race, ethnic, social, and sex disparities in post-ICH CI are also currently lacking, as is a clear depiction of how impaired domains may change over time. The design and implementation of future cohorts need to address these laminations such that disparate burden of post-ICH CI across population sub-groups can be studied and mitigated.

While the present review provides these suggestions, limitations within this study need to be acknowledged as well. First, the initial search mechanism was limited to the PubMed and ScienceDirect databases. Second, while data was assessed as thoroughly as possible some relevant information may have been lost through the exclusion of articles written in non-English languages. Finally, although efforts were made to investigate results, an effective meta-analysis could not be performed due to the variability in methods between papers. Future research should seek to expand on the present review through the inclusion of additional databases and non-English research, and it is our hope that increased standardization will allow for true meta-analysis to be performed in the future.

A two-stage systematic literature review was performed to comprehensively summarize current evidence on post-ICH CI. Evidence currently available in literature depicts a high rate of CI in the acute phase (<4 weeks), which drops to lower levels at 3 and 6 months. Rate of post-ICH CI then increases over time, although it seems to plateau at a level lower than that observed during the acute phase. Impairment onset generally appears to associate more with demographic and genetic variables and extent of ICH related cortical damage. The methods, timepoints, and markers used to assess CI are highly varied and limit the ability for quantitative evidence synthesis. This calls for consistent methods to be established for future investigations of post-ICH CI and dementia across heterogenous clinical phenotypes and population sub-groups.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Author Contributions

TP performed data collection, extraction, and assessment, as well as manuscript writing. FV and TP designed the search strategy and focus. FV oversaw data collection, methods, and writing. FV, JM, and AP reviewed data quality. V-AL, MT, JM, AP, DW, SS, MS, and FV contributed to data interpretation and provided major revisions. All the authors contributed to manuscript revision and read and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

CI, Cognitive impairment.

References

1. An SJ, Kim TJ, Yoon B-W. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. J Stroke. (2017) 19:3–10. doi: 10.5853/jos.2016.00864

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Caceres JA, Goldstein JN. Intracranial hemorrhage. Emerg Med Clin North Am. (2012) 30:771–94. doi: 10.1016/j.emc.2012.06.003

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Roh D, Sun C-H, Schmidt JM, Gurol E, Murthy S, Park S, et al. Primary intracerebral hemorrhage: a closer look at hypertension and cerebral amyloid angiopathy. Neurocrit Care. (2018) 29:77–83. doi: 10.1007/s12028-018-0514-z

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Øie LR, Madsbu MA, Solheim O, Jakola AS, Giannadakis C, Vorhaug A, et al. Functional outcome and survival following spontaneous intracerebral hemorrhage: a retrospective population-based study. Brain Behav. (2018) 8:e01113. doi: 10.1002/brb3.1113

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Banerjee G, Summers M, Chan E, Wilson D, Charidimou A, Cipolotti L, et al. Domain-specific characterisation of early cognitive impairment following spontaneous intracerebral haemorrhage. J Neurol Sci. (2018) 391:25–30. doi: 10.1016/j.jns.2018.05.015

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Corraini P, Henderson VW, Ording AG, Pedersen L, Horváth-Puhó E, Sørensen HT. Long-term risk of dementia among survivors of ischemic or hemorrhagic stroke. Stroke. (2017) 48:180–6. doi: 10.1161/STROKEAHA.116.015242

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Aam S, Einstad MS, Munthe-Kaas R, Lydersen S, Ihle-Hansen H, Knapskog A-B, et al. Post-stroke Cognitive impairment-impact of follow-up time and stroke subtype on severity and cognitive profile: the Nor-COAST Study. Front Neurol. (2020) 11:699. doi: 10.3389/fneur.2020.00699

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Sayers A. Tips and tricks in performing a systematic review. Br J Gen Pract. (2007) 57:425. doi: 10.3399/096016407782604938

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Viswanathan M, Patnode CD, Berkman ND, Bass EB, Chang S, Hartling L, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Rockville, MD: Agency for Healthcare Research and Quality (2017). Available online at: https://effectivehealthcare.ahrq.gov/topics/methods-bias-update/methods/ (cited December 29, 2020).

PubMed Abstract

10. Altieri M, Di Piero V, Pasquini M, Gasparini M, Vanacore N, Vicenzini E, et al. Delayed poststroke dementia: a 4-year follow-up study. Neurology. (2004) 62:2193–7. doi: 10.1212/01.WNL.0000130501.79012.1A

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Barba R, Martínez-Espinosa S, Rodríguez-García E, Pondal M, Vivancos J, Del Ser T. Poststroke dementia : clinical features and risk factors. Stroke. (2000) 31:1494–501. doi: 10.1161/01.STR.31.7.1494

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Benedictus MR, Hochart A, Rossi C, Boulouis G, Hénon H, van der Flier WM, et al. Prognostic factors for cognitive decline after intracerebral hemorrhage. Stroke. (2015) 46:2773–8. doi: 10.1161/STROKEAHA.115.010200

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Biffi A, Bailey D, Anderson CD, Ayres AM, Gurol EM, Greenberg SM, et al. Risk factors associated with early vs. delayed dementia after intracerebral hemorrhage. JAMA Neurol. (2016) 73:969–76. doi: 10.1001/jamaneurol.2016.0955

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Koning I, Kooten F, Koudstaal PJ, Dippel D. Diagnostic value of the Rotterdam-CAMCOG in post-stroke dementia. J Neurol Neurosurg Psychiatry. (2005) 76:263–5. doi: 10.1136/jnnp.2004.039511

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Douiri A, Rudd AG, Wolfe CDA. Prevalence of poststroke cognitive impairment. Stroke. (2013) 44:138–45. doi: 10.1161/STROKEAHA.112.670844

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Gong L, Gu Y, Yu Q, Wang H, Zhu X, Dong Q, et al. Prognostic factors for cognitive recovery beyond early Poststroke Cognitive Impairment (PSCI): a prospective cohort study of spontaneous intracerebral hemorrhage. Front Neurol. (2020) 11:278. doi: 10.3389/fneur.2020.00278

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. (2018) 49:491–7. doi: 10.1161/STROKEAHA.117.016990

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Griauzde J, Lisabeth LD, Li C, Sanchez BN, Case E, Garcia NM, et al. A population-based study of intracerebral hemorrhage survivors' outcomes. J Stroke Cerebrovasc Dis. (2019) 28:49–55. doi: 10.1016/j.jstrokecerebrovasdis.2018.09.005

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Ihle-Hansen H, Thommessen B, Wyller T, Engedal K, Øksengård A, Stenset V, et al. Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment. Dement Geriatr Cogn Disord. (2011) 32:401–7. doi: 10.1159/000335361

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. (2004) 256:240–6. doi: 10.1111/j.1365-2796.2004.01380.x

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Koivunen R-J, Harno H, Tatlisumak T, Putaala J. Depression, anxiety, and cognitive functioning after intracerebral hemorrhage. Acta Neurol Scand. (2015) 132:179–84. doi: 10.1111/ane.12367

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Madureira S, Guerreiro M, Ferro JM. Dementia and cognitive impairment three months after stroke. Eur J Neurol. (2001) 8:621–7. doi: 10.1046/j.1468-1331.2001.00332.x

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Moulin S, Labreuche J, Bombois S, Rossi C, Boulouis G, Hénon H, et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol. (2016) 15:820–9. doi: 10.1016/S1474-4422(16)00130-7

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Nakase T, Sasaki M, Yoshioka S, Ikeda Y, Suzuki A. Risk of cognitive impairment in acute phase of intracerebral haemorrhage. Int J Stroke. (2013) 8:E15. doi: 10.1111/ijs.12104

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Planton M, Saint-Aubert L, Raposo N, Branchu L, Lyoubi A, Bonneville F, et al. High prevalence of cognitive impairment after intracerebral hemorrhage. PloS One. (2017) 12:e0178886. doi: 10.1371/journal.pone.0178886

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Tang WK, Chan SSM, CH F.K., Ungvari GS, Ka SW, Kwok TCY, et al. Frequency and determinants of poststroke dementia in Chinese. Stroke. (2004) 35:930–5. doi: 10.1161/01.STR.0000119752.74880.5B

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Tveiten A, Ljøstad U, Mygland Å, Naess H. Functioning of long-term survivors of first-ever intracerebral hemorrhage. Acta Neurol Scand. (2014) 129:269–75. doi: 10.1111/ane.12185

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Xiong L, Charidimou A, Pasi M, Boulouis G, Pongpitakmetha T, Schirmer MD, et al. Predictors for late post-intracerebral hemorrhage dementia in patients with probable cerebral amyloid angiopathy. J Alzheimers Dis. (2019) 71:435–42. doi: 10.3233/JAD-190346

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Arauz A, Rodríguez-Agudelo Y, Sosa AL, Chávez M, Paz F, González M, et al. Vascular cognitive disorders and depression after first-ever stroke: the Fogarty-Mexico Stroke Cohort. Cerebrovasc Dis Basel Switz. (2014) 38:284–9. doi: 10.1159/000366471

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Nakano Y, Deguchi K, Yamashita T, Morihara R, Matsuzono K, Kawahara Y, et al. High incidence of dementia conversion than stroke recurrence in poststroke patients of late elder society. J Stroke Cerebrovasc Dis. (2015) 24:1621–8. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.037

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Nys GMS, van Zandvoort MJE, de Kort PLM, Jansen BPW, de Haan EHF, Kappelle LJ. Cognitive disorders in acute stroke: prevalence and clinical determinants. Cerebrovasc Dis Basel Switz. (2007) 23:408–16. doi: 10.1159/000101464

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Qureshi AI, Chughtai M, Malik AA, Bezzina C, Suri MFK. Incidental asymptomatic intracerebral hemorrhages and risk of subsequent cardiovascular events and cognitive decline in elderly persons. J Stroke Cerebrovasc Dis. (2015) 24:1217–22. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.020

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Su C-Y, Chen H-M, Kwan A-L, Lin Y-H, Guo N-W. Neuropsychological impairment after hemorrhagic stroke in basal ganglia. Arch Clin Neuropsychol. (2007) 22:465–74. doi: 10.1016/j.acn.2007.01.025

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Espinosa del Pozo PH, Espinosa PS, Donadi EA, Martinez EZ, Salazar-Uribe JC, Guerrero MA, et al. Cognitive decline in adults aged 65 and older in Cumbayá, Quito, Ecuador: prevalence and risk factors. Cureus 10:e3269. doi: 10.7759/cureus.3269

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Miller JH, Wardlaw JM, Lammie GA. Intracerebral haemorrhage and cerebral amyloid angiopathy: CT features with pathological correlation. Clin Radiol. (1999) 54:422–9. doi: 10.1016/S0009-9260(99)90825-5

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Sakai K, Ueda M, Fukushima W, Tamaoka A, Shoji M, Ando Y, et al. Nationwide survey on cerebral amyloid angiopathy in Japan. Eur J Neurol. (2019) 26:1487–93. doi: 10.1111/ene.14031

PubMed Abstract | CrossRef Full Text | Google Scholar

37. You S, Wang X, Lindley RI, Robinson T, Anderson CS, Cao Y, et al. Early cognitive impairment after intracerebral hemorrhage in the INTERACT1 Study. Cerebrovasc Dis Basel Switz. (2017) 44:320–4. doi: 10.1159/000481443

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Garcia PY, Roussel M, Bugnicourt JM, Lamy C, Canaple S, Peltier J, et al. Cognitive impairment and dementia after intracerebral hemorrhage: a cross-sectional study of a hospital-based series. J Stroke Cerebrovasc Dis. (2013) 22:80–6. doi: 10.1016/j.jstrokecerebrovasdis.2011.06.013

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. (2004) 35:1415–20. doi: 10.1161/01.STR.0000126807.69758.0e

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Li C-H, Chang Y-H, Chou M-C, Chen C-H, Ho B-L, Hsieh S-W, et al. Factors of post-stroke dementia: a nationwide cohort study in Taiwan. Geriatr Gerontol Int. (2019) 19:815–22. doi: 10.1111/ggi.13725

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Banerjee G, Wilson D, Ambler G, Osei-Bonsu AK, Shakeshaft C, Surabhika L, et al. Cognitive impairment before intracerebral hemorrhage is associated with cerebral amyloid angiopathy. Stroke. (2018) 49:40–5. doi: 10.1161/STROKEAHA.118.021077

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke. (1986) 17:1078–83. doi: 10.1161/01.STR.17.6.1078

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Fewel ME, Thompson BG, Hoff JT. Spontaneous intracerebral hemorrhage: a review. Neurosurg Focus. (2003) 15:1–16. doi: 10.3171/foc.2003.15.4.0

CrossRef Full Text | Google Scholar

44. Alonso A, de Larriva APA. Atrial fibrillation, cognitive decline and dementia. Eur Cardiol Rev. (2016) 11:49–53. doi: 10.15420/ecr.2016:13:2

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ Can Med Assoc J. (2012) 184:E329–E36. doi: 10.1503/cmaj.111173

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. (2008) 29:494–511. doi: 10.1210/er.2007-0034

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Case NF, Charlton A, Zwiers A, Batool S, McCreary CR, Hogan DB, et al. Cerebral amyloid angiopathy is associated with executive dysfunction and mild cognitive impairment. Stroke. (2016) 47:2010–6. doi: 10.1161/STROKEAHA.116.012999

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Goldberg TE, Huey ED, Devanand DP. Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies. Nat Commun. (2020) 11:4727. doi: 10.1038/s41467-020-18198-x

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. (2013) 9:106–18. doi: 10.1038/nrneurol.2012.263

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Emerson E. Deprivation, ethnicity and the prevalence of intellectual and developmental disabilities. J Epidemiol Community Health. (2012) 66:218–24. doi: 10.1136/jech.2010.111773

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Lurie N, Dubowitz T. Health disparities and access to health. JAMA. (2007) 297:1118–21. doi: 10.1001/jama.297.10.1118

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke. Stroke. (2005) 36:374–86. doi: 10.1161/01.STR.0000153065.39325.fd

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: intracerebral hemorrhage, cognitive impairment, dementia, outcome, stroke, cerebral small vessel disease

Citation: Potter T, Lioutas V-A, Tano M, Pan A, Meeks J, Woo D, Seshadri S, Selim M and Vahidy F (2021) Cognitive Impairment After Intracerebral Hemorrhage: A Systematic Review of Current Evidence and Knowledge Gaps. Front. Neurol. 12:716632. doi: 10.3389/fneur.2021.716632

Received: 28 May 2021; Accepted: 02 August 2021;
Published: 27 August 2021.

Edited by:

David J. Seiffge, University Hospital Bern, Switzerland

Reviewed by:

Hsin-Hsi Tsai, National Taiwan University Hospital Bei-Hu Branch, Taiwan
Myzoon Ali, University of Glasgow, United Kingdom
Craig S. Anderson, University of New South Wales, Australia

Copyright © 2021 Potter, Lioutas, Tano, Pan, Meeks, Woo, Seshadri, Selim and Vahidy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Farhaan Vahidy, fvahidy@houstonmethodist.org